Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis-Reference-Cited by-同舟云学术

Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis

Published:2024-07-23 Issue: Volume: Page:
ISSN:0937-941X
Container-title:Osteoporosis International
language:en
Short-container-title:Osteoporos Int

Author:

Reginster Jean-Yves^ORCID,Czerwinski Edward,Wilk Krzysztof,Borowy Przemysław,Strzelecka Anna,Budlewski Tomasz,Janowska-Maus Monika,Szymanowski Krzysztof^ORCID,Kwiatek Joanna,Postol Svitlana,Põder Airi,Supronik Jerzy,Kim SungHyun,Suh JeeHye,Han NooRi,Kim NaHyun,Bae SeoHee,Silverman Stuart L.^ORCID

Funder

Celltrion

Cedars-Sinai Medical Center

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00198-024-07161-x.pdf

Reference26 articles.

1. Salari N, Ghasemi H, Mohammadi L, Behzadi MH, Rabieenia E, Shohaimi S, Mohammadi M (2021) The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res 16:609

2. Borgström F, Karlsson L, Ortsäter G et al (2020) Fragility fractures in Europe: burden, management and opportunities. Arch Osteoporos 15:59

3. Tarantino U, Cariati I, Greggi C et al (2022) Gaps and alternative surgical and non-surgical approaches in the bone fragility management: an updated review. Osteoporos Int 33:2467–2478

4. Williams SA, Daigle SG, Weiss R, Wang Y, Arora T, Curtis JR (2021) Economic burden of osteoporosis-related fractures in the US Medicare population. Ann Pharmacother 55:821–829

5. Eastell R, O’Neill TW, Hofbauer LC, Langdahl B, Reid IR, Gold DT, Cummings SR (2016) Postmenopausal osteoporosis. Nat Rev Dis Primers 2:16069